Background: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic function is limited. This study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulating factor (G-CSF) in patients with acute myocardial infarction.Methods: The 'MAGIC Cell-5-Combination Cytokine Trial' is a multicenter, prospective, randomized, 3-arm, controlled trial with blind evaluation of the endpoints. A total of 116 patients will randomly receive one of the following three treatments: an intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G-CSF (n = 58), an intracoronary infusion of peripheral blood stem cells mobilized with G-CSF alone (n = 29), or conventional therapy (n = 29) at phase I. Patients with left ventricular ejection fraction < 45% at 6 months, in the patients who received stem cell therapy at phase I, will receive repeated cell therapy at phase II. The objectives of this study are to evaluate the safety and efficacy of combination cytokine therapy with erythropoietin and G-CSF (phase I) and repeated progenitor/stem cell treatment (phase II).Discussion: This is the first study to evaluate the safety and efficacy of combination cytokine based progenitor/stem cell treatment.Trial registration: http://www.ClinicalTrials.gov identifier: NCT00501917.
Bibliographical noteFunding Information:
This study was supported by a grant from the stem cell research center, Seoul, Republic of Korea (SC4210, for YBP) and a grant from the Innovative Research Institute for Cell Therapy, Seoul National University Hospital (A062260, for HJK, HSK, and YBP), sponsored by the Ministry of Health, Welfare & Family, Republic of Korea. Funding did influence study design and the writing and submission of the manuscript.
All Science Journal Classification (ASJC) codes
- Medicine (miscellaneous)
- Pharmacology (medical)